Rapid Micro Biosystems, Inc. · NASDAQ:RPID
Rapid Micro Biosystems — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
18 slides from Rapid Micro Biosystems's conference presentation, Jan 15, 2026
Slide 1: 44th Annual J.P. Morgan Healthcare Conference
44th Annual J.P. Morgan Healthcare Conference Rob Spignesi, President & CEO January 15, 2026 RAPID M ICRO BIOSYSTEMS NASDAQ: RPID © 2025, Rapid Micro Rapid Biosystems, Micro Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered Biosystems trademarks of Rapid Micro Biosystems, Inc., and th
Slide 2: Disclaimers
Disclaimers This presentation has been prepared by Rapid Micro Biosystems, Inc. (the “Company”) solely for informational purposes. This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exch
Slide 3: Our vision
We are transforming a critical, Our regulated part of the global pharmaceutical manufacturing C process, bringing microbial vision quality control into the 21st century. The new standard in microbial quality control Rapid Micro Biosystems © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS
Slide 4: The standard in automating microbial quality control
2025 REVENUE1 GLOBAL SYSTEMS 1 CUSTOMERS $33.6M 190 75% Total Revenue Cumulative Placements Top 20 Global Pharma2 The standard 20% 155 86% Year / Year Growth Cumulative Validations Approved CAR-T Manufacturers in automating microbial $17.8M ~20 quality control Recurring Revenue Countries © 2025, Rap
Slide 5: 2025 revenue guidance exceeded with record fourth quarter
2025 revenue guidance exceeded with record fourth quarter SELECT HIGHLIGHTS Record quarterly revenue; exceeded full year guidance following guidance increase (FY’25); 13th quarter of meeting / R E S U LT S Q4 20251 FY 20251 exceeding revenue guidance. Total Revenue $11.3M $33.6M Strong recurring rev
Slide 6: MQC has not kept up with pharma industry innovation
MQC has not kept up with pharma industry innovation FACTORS DRIVING CHANGE Scientific and Growing demand for Faster & leaner Data integrity & Regulatory + + + + technology innovation more complex therapies manufacturing security focus scrutiny TODAY TODAY TODAY Discovery & research Bioprocessing & m
Slide 7: Challenges in a traditional microbial quality control (MQC) lab
Challenges in a traditional microbial quality control (MQC) lab High volume testing and mandated by regulators Insecure and lacking data integrity Subjective and prone to human error Manual, paper-based and slow Rapid Micro Biosystems © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® an
Slide 8: Introducing the Growth Direct platform
Introducing the Growth Direct® platform The only fully automated, high-throughput and secure MQC solution… …delivering a compelling value proposition Data Supports global quality regulatory compliance Proprietary Integrity and improved data handling and management Consumables Enables faster decision
Slide 9: Growth Direct transforms and modernizes MQC
Growth Direct® transforms and modernizes MQC MANUAL WORKFLOW 1. 2. 3. 4. 5. 6. 7. 8. Manual & subject to error PULL QC FILL OUT PREPARE LOAD PULL PERFORM RECORD RETURN TEST FORM ASSAY INFO SAMPLES INCUBATOR SAMPLES COUNTS COUNTS SAMPLES 15 steps 9. 10. 11. 12. 13. 14. 15. 5-14 days to result / test
Slide 10: The Growth Direct System brings MQC into the 21st Century
The Growth Direct® System brings MQC into the 21st Century FACTORS DRIVING CHANGE Scientific and Growing demand for Faster & leaner Data integrity & Regulatory + + + + technology innovation more complex therapies manufacturing security focus scrutiny TODAY QC & ANALYSIS TODAY TODAY Discovery & resea
Slide 11: Market forces pushing pharma industry to automation
Market forces pushing pharma industry to automation Expanding Large and Regulatory Industry Manufacturing Growing Market Pressure Change Capacity, Especially $5B annual recurring Increasing regulatory Growth in complex U.S. Reshoring revenue + $5B global scrutiny and biologics and cell & system oppo
Slide 12: Growth strategy focused on land and expand augmented by innovation
Growth strategy focused on land and expand augmented by innovation GROW NEW DRIVE ENTERPRISE EXPAN D INT O L AU N C H N EW PU R SU E AD J A C E N T C U ST O M ER AD O PT I O N DEPLOYMENTS NEW GEOGRAPH IES PRODUCTS M AR K ET S AN D SER VI C E S BIO PHARMA + Sample (incl. cell Site automation & gene)
Slide 13: Customer base includes 75% of the top 20 global pharma companies
Customer base includes 75% of the top 20 global pharma companies1 with significant growth potential CUSTOM ER SEGM ENTS W ITH ESTABLISHED USE GLOBAL SITES W ITH GROW TH DIRECT SYSTEM S Biologics Cell & Gene Therapy / CAR-T CDMO Personal Care Products Small Molecules 190 75% cumulative of top 20 syst
Slide 14: 7th Annual Growth Direct Day – Driving Progress Together
7th Annual Growth Direct Day – Driving Progress Together Annual 2-day event brings together industry thought-leaders, customers and prospective customers Largest event in seven-year history with over 25 companies participating and approximately 100 attendees from the U.S., Europe and Asia On-site to
Slide 15: Strong and consistent revenue growth and margin improvement
Strong and consistent revenue growth and margin improvement REVENUE Revenue Growth Drivers Recurring ~$33.6M • New customer wins Non-recurring $28.1M • Global deployments at existing customers $22.5M • Merck MilliporeSigma partnership (distribution) $17.1M • New products and services • Strong consum
Slide 16: Strategically well positioned for growth and margin expansion in 2026 and beyond
Strategically well positioned for growth and margin expansion in 2026 and beyond • Market leading product with strong growth and global adoption by top tier customer base • Commercial momentum driven by multi-system orders and market tailwinds • Strong and growing recurring revenue drive by consumab
Slide 17: Creating the future of rapid, secure MQC automation
Creating the future of rapid, secure MQC automation to drive sustainable, long-term growth and shareholder value Growth Direct® is the industry-leading platform Chosen by 75% of the top 20 global pharma Operating behind companies1 with significant Enabling advanced strong barriers to entry commercia
Slide 18: Thank you
Thank you © 2025, Rapid Micro Rapid Biosystems, Micro Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered Biosystems trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Rapid Micro Biosystems — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix